Supplement Reviews  |  Fat Burners & Weight Loss  |  Bodybuilding Guides  |  Training & Workout  |  Health & Nutrition  |  Diet & Fitness Articles  |  User Reviews
Fat Burners & Diet Pills

Biotest Hot Rox Extreme Review
Bitter Orange - Citrus Aurantium
Cellucor D4 Thermal Shock
Chitosan - What is Chitosan?
Chromium Picolinate Weightloss
Coleum Forskohlii Extract
Fat Burners Review guide -1
Fat Burners Review guide - 2
GHR15 Anti Aging Review
GHR15 Supplement Review (2)
GHR Side Effects
Green Tea Diet Patch
Hoodia Gordonii Diet Pill Review
Hoodia Gordonii Diet Pill Guide - 1
Hoodia 750 & Hoodia Dex L10 - 2
Desert Burn Hoodia Review - 3
Guarana Side Effects & Benefits
Hoodoba Pure Review - 4
Hydroxadrine Review
Instone LeanFire Review
Isatori Flash Point Fat Burner - 1
Isatori Flash Point Fat Burner - 2
Lean System 7 Review
Lipoderm Ultra Review
Lose Fat & Love Handles
NutraSport Cutting Gel Review
Nutrex Lipo 6 Review (Lipo 6x)
Nutrex Lipo 6 for Her Review
Fat Burners Potential Downfall
Ephedrine Risks and Danger
Oolong Tea and Weight Loss
Prolab Metabolic Thyrolean
Pyruvate Supplement Review
Relacore Review - 1
Relacore Side Effects - 2
Slimquick Review - 1
Slim Quick Review - 2
Slimquick Extreme Review - 3
Slimquick Cleanse Review - 4
Twinlab Ripped Fuel Review
Twinlab Ripped Fuel Side Effects
Stacker 2 Fat Burner Review
Stacker 2 Ephedra Free Review
Stacker 3 Fat Burner Review
Tea Lite Weight Loss Patch
Tonalin CLA Review
Tonalin CLA Side Effects & Benefits
Tonalin CLA Studies
Trimspa Review
VPX Meltdown Review
VPX Redline Review
Wu Yi Tea Review
Yerba Mate Benefit, Side Effects -1
Yerba Mate Tea Drinking - 2
Zantrex 3 Review
Zantrex 3 Side Effects
Zotrin For Women and Men

Xenadrine EFX & RFA-1

New Xenadrine RFA-1 Review
Xenadrine EFX Review
Xenadrine NRG 8 Hour Revew
Xenadrine information
Xenadrine RFA 1 (Original)
Xenadrine side effects
Thermogenics fat loss

MuscleTech Hydroxycut

Hydroxycut Review
Hydroxycut Hardcore Review
Hydroxycut Max for Women
Hydroxycut Side Effects
Hydroxycut With Hoodia
Hydroxycut Acai Reviews
Hydroxycut FAQ

Weight Loss & Fat Loss

Accelis Review
Adipex Diet Pill Information
Adipex Side Effects
Alli Weight Loss Pill Review
Clenbuterol Weight Loss
Clenbuterol Side Effects
Cortislim Review
Dexatrim Max Complex 7 Review
Fenphedra Review
Glucomannan
Hollywood Miracle Diet Review
Lipozene Review
Leptopril Diet Pill Review
Leptovox Review
Lipovox Review
Meridia Weight Loss Pill
Meridia Side Effects
Miracleburn Review
Nuphedrine Review
Orovo Detox Weight Loss Pill
Phentermine Diet Pill Information
Phentermine Diet Pill Studies
Phentermine Side Effects
Phentermine Types
Quick Fat Loss Tips
Sensa Weight Loss Reviews
Sesamin Review - Sesamin Oil
Slimshots Review
Weight Loss Program 1
Weight Loss Program 2
Xenical Weight Loss Pill
Xenical Side Effects

Diets & Diet Plans

Abs Diet Plan
Atkins Diet
Biggest Loser Diet Plan
Bill Phillips Body For Life
Blood Type Diet (A B O AB)
Bob Greene's Diet
Burn the Fat Feed the Muscle
Calorie Shifting Diet Plan Review
Curves Diet
Dash Diet
Dr. Phil Diet Plan
Fat Flush Diet Plan
Fat Smash Diet
GI Diet
Holy Grail Body Transformation
L.A. Weight Loss
Mediterranean Diet
Nutrisystem Diet
Slim Fast Diet
Sonoma Diet
South Beach Diet
The Truth About Abs Review
Zone Diet

Phentermine Prescription Diet Pill Studies

Phentermine Weight Loss Studies

Phentermine is a prescription diet pill that's used for weight loss, and is mainly used as an appetite suppressant. Since receiving FDA approval in 1959, Phentermine has been used worldwide as a prescription diet pill to help people lose weight.

Various studies have been done on Phentermine to study its effectiveness for weight loss, and to determine possible side effects of using Phentermine. In this article, we highlight several Phentermine studies done in the past that evaluate the effectiveness of the Phentermine prescription diet pill.

Phentermine Study I (Phen Fen vs. Phen Flu)

Study origin: Department of Medicine and Nutritional Sciences, University of Wisconsin, Madison, WI, USA.

Title: Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status (International Journal of Obesity advance online publication, 5 December 2006;)

Researchers: Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL.

Phentermine Background: Obesity treatment with single drugs produces weight losses of about 8-10% of initial body weight. Few studies of combinations of drugs for treating obesity have been published. The combination of phentermine, an adrenergic agent, and fenfluramine, a serotonergic agent, (phen-fen) produced weight losses of about 15% of initial body weight. Fenfluramine is no longer available because it was associated with cardiac valve lesions. Phentermine-fluoxetine (phen-flu) has been proposed as an alternative for phen-fen.

Objective: To compare the efficacy of treatment and prevalence of cardiac valve abnormalities on phen-flu vs phen-fen.

Design: Retrospective chart review of all patients treated for at least 3 months with phen-flu (N=97) to a random sample of patients treated with phen-fen (N=98) in the Clinical Nutrition Clinic at the University of Wisconsin. Comparison of echocardiograms in all patients treated solely with phen-flu (N=21) to a random sample of patients treated with phen-fen (N=47), and to a group of subjects never treated with obesity drugs (N=26).

Results: With last observation carried forward analysis (LOCF), at 6 months of treatment the phen-fen patients lost 12.6+/-0.6% of baseline weight and phen-flu patients lost 9.0+/-0.6% (P<0.001). With completers analysis, there were no significant differences in weight loss as a percent of baseline weight at 6 months (14.4+/-0.6 vs 13.3+/-0.9%). LOCF decreases in body mass index (BMI) at 6 months were -5.3 and -3.6 kg/m(2) for phen-fen and phen-flu, respectively (P<0.001), and 6.2+/-0.3 vs 5.4+/-0.4 kg/m(2), respectively, for the completers analysis (P - NS).

Dropout rate at 6 months was higher in phen-flu subjects (44 vs 28%). In subjects without atherosclerosis of valves (presumably pre-existing), cardiac valve lesions occurred in eight of 38 phen-fen subjects and in none of 15 phen-flu subjects or 25 control subjects who had not been treated with drugs.

Conclusions: The combination of phentermine and fluoxetine was not as effective as phen-fen, but was not associated with cardiac valve lesions. Longer term, larger scale studies of phen-flu are warranted.

Phentermine Study II (Phentermine 37.5)

Study Origin: Department of Family Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.

Title: Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.

Researchers: Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR.

Objective: Phentermine, an appetite suppressant, has been widely applied in Korea since 2004. However, there have been relatively few reports about the efficacy and the safety of phentermine in Korea. The aim of this study is to verify the effect of phentermine on weight reduction and the safety in Korean patients.

Design: This randomized, double-blind, placebo- controlled study had been performed between February and July, 2005, in Seoul on 68 relatively healthy obese adults whose body mass index was 25 kg/m2 or greater. They received phentermine-HCl 37.5 mg or placebo once daily with behavioral therapy for obesity.

Results: The primary endpoints were the changes of body weight and waist circumference from the baseline in the intention-to-treat population. Mean decrease of both body weight and waist circumference in phentermine-treated subjects were significantly greater than that of placebo group (weight: -6.7 +/- 2.5 kg, p < 0.001; waist circumference: -6.2 +/- 3.5 cm, p < 0.001). Significant number of subjects in phentermine group accomplished weight reduction of 5% or greater from the baseline and 10% or more (p < 0.001).

There were no significant differences in systolic and diastolic blood pressure between the groups (p = 0.122 for systolic BP; p = 0.219 for diastolic BP). Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group. Most side effects of phentermine were mild to moderate in intensity.

Conclusion: Short-term phentermine administration induced significant weight reduction and reduction of waist circumference without clinically problematic adverse events on relatively healthy Korean obese people.

Phentermine Study III (Phen-Fen)

Study Origin: Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA.

Title: The fen-phen finale: a study of weight loss and valvular heart disease.

Researchers: Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ, Foster GD, Aber JL.

Objective: To assess weight loss, as well as the prevalence of valvular heart disease, in 21 obese women who completed 2 years of treatment by fenfluramine and phentermine (fen-phen) in June 1997.

Design: Patients were 21 of 22 women who had completed a 1-year, open-label trial of fen-phen combined with lifestyle modification. This study describes the results of a second year of treatment. The presence of valvular heart disease, defined as aortic regurgitation of mild or greater severity and/or mitral regurgitation of moderate or greater severity, was assessed using two-dimensional, color Doppler and pulsed- and continuous-wave Doppler examinations.

Results: At 2 years, the 21 patients had a mean reduction in initial weight of 13.9 + 10.0%, which was significantly (p<0.001) smaller than their 1-year loss of 17.1 +/- 8.7%. Nine of 21 patients reported that they took fen-phen irregularly during the last 4 months of the study because of fears of developing health complications. These nine patients had a 2-year weight loss of 8.7 +/- 7.5%, compared with a significantly (p<0.04) larger loss of 17.6 +/- 10.5% for participants who reported taking medication regularly. Six of 20 (30%) patients met criteria for valvular heart disease. None of the six had signs or symptoms of this condition.

Discussion: Fenfluramine was withdrawn from the market on September 15, 1997 because of concerns that it was associated with valvular heart disease. The present findings are discussed in terms of the potentially favorable long-term benefits of combining lifestyle modification with weight loss medications that are both safe and effective.